UMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis

被引：0
|
作者：
Kaminski, H. [1 ]
Zhao, C. [2 ]
zu Horste, G. Meyer [3 ]
O'Connor, K. [4 ]
Klingelschmitt, G. [5 ]
Krumova, P. [5 ]
Bolt, S. [6 ]
Vodopivec, I. [5 ]
Murai, H. [7 ]
机构：
[1] George Washington Univ, Washington, DC USA
[2] Fudan Univ, Shanghai, Peoples R China
[3] Univ Munster, Munster, Germany
[4] Yale Univ, New Haven, CT USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Roche Prod, Welwyn Garden City, Herts, England
[7] Univ Hlth & Welf, Narita, Japan
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.162
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.92
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [31] Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial
    Howard, James F. Jr Jr
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Perk, Stojan
    Margania, Temur
    Murai, Hiroyuki
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    LANCET NEUROLOGY, 2021, 20 (07): : 526 - 536
  • [32] PHASE 3 TRIAL INVESTIGATING IMPACT OF INTRAVENOUS EFGARTIGIMOD IN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY NEGATIVE GENERALIZED MYASTHENIA GRAVIS
    Guptill, Jeffrey
    Jimenez, Rosa H.
    Howard, James F., Jr.
    MUSCLE & NERVE, 2024, 70 (03) : 538 - 538
  • [33] Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
    Jared
    Guptill, Jeffrey
    Jimenez, Rosa H.
    Howard, James F., Jr.
    ANNALS OF NEUROLOGY, 2024, 96 : S270 - S271
  • [34] ACETYLCHOLINE-RECEPTOR ANTIBODY CHARACTERISTICS IN MYASTHENIA-GRAVIS .3. PATIENTS WITH LOW ANTI-ACHR ANTIBODY-LEVELS
    VINCENT, A
    NEWSOMDAVIS, J
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1985, 60 (03): : 631 - 636
  • [35] The influence of anti-human IL-6 receptor antibody on bone metabolism in rheumatoid arthritis patients
    Hashimoto, J
    Tsuboi, H
    Yoshikawa, H
    Tomita, T
    Ochi, T
    Yoshizaki, K
    Nishimoto, N
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S216 - S216
  • [36] HIGH IL-6 GENE-EXPRESSION AND PRODUCTION BY CULTURED HUMAN THYMIC EPITHELIAL-CELLS FROM PATIENTS WITH MYASTHENIA-GRAVIS
    COHENKAMINSKY, S
    DELATTRE, RM
    DEVERGNE, O
    KLINGELSCHMITT, I
    EMILIE, D
    GALANAUD, P
    BERRIH-AKNIN, S
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 681 : 97 - 99
  • [37] Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
    Parums, Dinah V.
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [38] Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway
    Ji, Yiyi
    Liu, Bo
    Chen, Lei
    Li, Ang
    Shen, Kai
    Su, Ruopeng
    Zhang, Weiwei
    Zhu, Yinjie
    Wang, Qi
    Xue, Wei
    CELLULAR ONCOLOGY, 2023, 46 (05) : 1445 - 1456
  • [39] Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
    Nowell, Mari A.
    Williams, Anwen S.
    Carty, Sarah A.
    Scheller, Juergen
    Hayes, Anthony J.
    Jones, Gareth W.
    Richards, Peter J.
    Slinn, Simon
    Ernst, Matthias
    Jenkins, Brendan J.
    Topley, Nicholas
    Rose-John, Stefan
    Jones, Simon A.
    JOURNAL OF IMMUNOLOGY, 2009, 182 (01): : 613 - 622
  • [40] Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease
    Mitsuyama, Keiichi
    Matsumot, Satoshi
    Masuda, Junya
    Yamasaki, Hiroshi
    Kuwaki, Kotaro
    Takedatsu, Hidetoshi
    Sata, Michio
    ANTICANCER RESEARCH, 2007, 27 (6A) : 3749 - 3756
12345